Version July 2025
Dry eye disease: Ophthalmic: Instill 1 drop into each eye every 12 hours.
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
Refer to adult dosing.
(For additional information see "Lifitegrast: Pediatric drug information")
Dry eye disease (DED): Adolescents ≥17 years: Ophthalmic: Instill 1 drop into each eye every 12 hours.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
>10%:
Gastrointestinal: Dysgeusia (5% to 25%)
Local: Application-site irritation (5% to 25%)
Ophthalmic: Decreased visual acuity (5% to 25%)
1% to 10%:
Nervous system: Headache (1% to 5%)
Ophthalmic: Blurred vision (1% to 5%), conjunctival hyperemia (1% to 5%), eye discharge (1% to 5%), eye discomfort (1% to 5%), eye irritation (1% to 5%), eye pruritus (1% to 5%), increased lacrimation (1% to 5%)
Respiratory: Sinusitis (1% to 5%)
Postmarketing: Hypersensitivity: Hypersensitivity reaction (including anaphylaxis and angioedema)
Hypersensitivity to lifitegrast or any component of the formulation.
Special Populations:
• Contact lens wearers: Remove contact lens prior to administration and wait 15 minutes before reinserting.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Ophthalmic [preservative free]:
Xiidra: 5% (5 ea)
No
Solution (Xiidra Ophthalmic)
5% (per each): $14.38
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Ophthalmic:
Xiidra: 5% (0.2 mL)
For topical ophthalmic use only. Remove contact lenses prior to administration and wait 15 minutes before reinserting. Do not touch the eye or surrounding area or any surface with the dropper tip to avoid contamination; discard single use container and unused solution after administration.
For topical ophthalmic use only. Remove contact lenses prior to administration. Supplied as a single-use container and should be used immediately after opening; a single container can be used for both eyes and then discarded after administration. Do not touch the eye or surrounding area or any surface with the dropper tip to avoid contamination. Contact lenses may be reinserted 15 minutes after lifitegrast instillation.
Dry eye disease: Treatment of the signs and symptoms of dry eye disease (DED).
None known.
There are no known significant interactions.
Systemic exposure following ophthalmic administration is low. In general, if ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease potential exposure to the fetus (Samples 1988).
It is not known if lifitegrast is excreted in breast milk, however systemic exposure following ophthalmic administration is low. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.
Lifitegrast binds to the integrin lymphocyte function-associated antigen-1 (LFA-1) and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1).
